S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
S&P 500   3,380.35 (+1.40%)
DOW   27,976.84 (+1.05%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   474.60 (+1.64%)
DIS   131.53 (+0.80%)
BAC   26.75 (-0.63%)
BA   175.47 (-2.59%)
Log in

NASDAQ:NEONeoGenomics Price Target & Analyst Ratings

$39.23
-0.11 (-0.28 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$38.42
Now: $39.23
$39.82
50-Day Range
$27.27
MA: $35.22
$40.32
52-Week Range
$18.52
Now: $39.23
$41.03
Volume562,600 shs
Average Volume990,304 shs
Market Capitalization$4.33 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.82

Analyst Ratings

NeoGenomics (NASDAQ:NEO) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for NeoGenomics in the last 12 months. Their average twelve-month price target is $35.22, suggesting that the stock has a possible downside of 10.22%. The high price target for NEO is $45.00 and the low price target for NEO is $9.00. There are currently 1 hold rating, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.133.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $35.22$31.00$33.71$24.67
Price Target Upside: 10.22% downside11.59% upside20.54% upside25.23% downside

NeoGenomics (NASDAQ:NEO) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

NeoGenomics (NASDAQ:NEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/29/2020Craig HallumBoost Price TargetIn-Line ➝ Buy$36.00 ➝ $42.00Low
7/29/2020SVB LeerinkBoost Price TargetOutperform$35.00 ➝ $45.00Low
7/29/2020Raymond JamesBoost Price TargetOutperform$32.00 ➝ $40.00Medium
7/29/2020BenchmarkBoost Price TargetBuy$35.00 ➝ $40.00High
7/29/2020Needham & Company LLCBoost Price TargetBuy$33.00 ➝ $39.00High
6/25/2020Bank of AmericaInitiated CoverageBuy$34.00High
5/15/2020CIBCDowngradeNeutral$11.00 ➝ $9.00Low
4/21/2020StephensInitiated CoverageOverweight$33.00High
2/28/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$35.00High
10/29/2019William BlairReiterated RatingOutperformLow
11/16/2018ScotiabankReiterated RatingBuy ➝ Average$24.00Low
6/21/2018BTIG ResearchReiterated RatingBuy$15.00High
3/13/2018Canaccord GenuityBoost Price Target$23.00 ➝ $24.00Medium
3/13/2018Royal Bank of CanadaBoost Price TargetOutperform$23.00 ➝ $24.00Medium
10/26/2017Janney Montgomery ScottReiterated RatingBuyN/A
8/24/2017GabelliInitiated CoverageBuy$9.00High
(Data available from 8/12/2018 forward)
This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.